Population pharmacokinetic and exposure–response analysis of apremilast in Japanese subjects with moderate to severe psoriasis

• Published in: Journal of dermatology Vol. 48; no. 11; pp. 1652 - 1664
• Main Authors: Okubo, Yukari, Ohtsuki, Mamitaro, Komine, Mayumi, Imafuku, Shinichi, Kassir, Nastya, Petric, Rosemary, Nemoto, Osamu
• Format: Journal Article
• Language: English
• Published: Tokyo Wiley Subscription Services, Inc 01.11.2021; John Wiley and Sons Inc
• Subjects: apremilast; Caucasian; Clinical outcomes; Inhibitor drugs; Japan; Original; Pharmacokinetics; Phosphodiesterase; Phosphodiesterase IV; Psoriasis

Apremilast is an orally available phosphodiesterase 4 inhibitor used for the treatment of moderate to severe psoriasis. The aims of this analysis were to develop a population pharmacokinetic (PPK) model of apremilast based on observed data from phase 1 studies combined with clinical trial data from...